P632: COMPARISON OF TREATMENT-EMERGENT ADVERSE EVENTS OF ACALABRUTINIB AND ZANUBRUTINIB IN CLINICAL TRIALS IN B-CELL MALIGNANCIES: A SYSTEMATIC REVIEW AND META-ANALYSIS
Steven R. Hwang(Mayo Clinic), Yucai Wang(Mayo Clinic), Jonas Paludo(WinnMed), Sameer A. Parikh(Mayo Clinic), Jacqueline Wang, Mazie Tsang(Mayo Clinic Hospital), Thomas M. Habermann(Mayo Clinic in Arizona), Shouhao Zhou(Pennsylvania State University), Richard Godby(Mayo Clinic), Shijia Zhang(Illinois CancerCare), Paul J. Hampel(Mayo Clinic), Saad S. Kenderian(Mayo Clinic in Arizona), Stephen M. Ansell(Mayo Clinic), Zizhong Tian(Pennsylvania State University), Grzegorz S. Nowakowski(Université Claude Bernard Lyon 1), Talal Hilal(WinnMed), David J. Inwards(Mayo Clinic), Wei Ding(Mayo Clinic), Eli Muchtar(Mayo Clinic), Gita Thanarajasingam(Mayo Clinic in Arizona), Javier Muñoz(The University of Texas MD Anderson Cancer Center), Yi Jiang(Pennsylvania State University), Xinyue Qi(Pennsylvania State University), Neil E. Kay(Mayo Clinic), José F. Leis(Mayo Clinic), Thomas E. Witzig(WinnMed)
Cited by 7
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
|Nature Medicine|2015|1.1k
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials
|JAMA Oncology|2019|829